S2CID 28782021
Food and Drug Administration (2024) 2
This product is supplied strictly for in vitro and laboratory research use

gut-driven MCAS) MTHFR, HNMT, MAOA SNPs Influence histamine clearance and neurotransmitter sensitivity Cytokine panel (IL-6, TNF-, IL-1) Indicates immune overactivation OAT (Organic Acids Test) May show clostridia overgrowth, mold, or neurotransmitter imbalances Stool testing (GI-MAP) Identifies pathogens or dysbiosis triggering mast cells Mycotoxin or mold panel Mold exposure is a major MCAS trigger Step 4: Diagnostic Criteria (per 2012 Consensus) A diagnosis of MCAS is made when all three of the following are met: Typical clinical symptoms affecting 2 organ systems Elevated mast cell mediator(s) during episodes (tryptase, histamine, prostaglandins, etc.) Clinical response to MCAS treatments , including antihistamines, cromolyn sodium, quercetin, or mast cell stabilizers Genetic Variants Associated with MCAS Susceptibility MCAS (Mast Cell Activation Syndrome) is not caused by a single gene mutation , but certain genetic variants can increase your susceptibility by impairing detoxification, immune regulation, or histamine metabolism

Results and treatment needs vary by patient